C-Rad AB (publ)

LON-0R44
London Stock Exchange
Electromedical and Electrotherapeutic Apparatus
Global Rank
#23776
Country Rank
#301
Market Cap
131.38 M
Price
49.11
Change (%)
1.11%
Volume
931

C-Rad AB (publ)'s latest marketcap:

131.38 M

As of 07/20/2026, C-Rad AB (publ)'s market capitalization has reached $131.38 M. According to our data, C-Rad AB (publ) is the 23776th most valuable company globally by market capitalization. Market capitalization, commonly referred to as market cap, represents the total market value of all outstanding shares of a publicly traded company and is often used as a measure of company value.

Market Cap 131.38 M
Revenue (ttm) 46.5 M
Net Income (ttm) 5.22 M
Shares Out 0
EPS (ttm) 0.16
Forward PE 17.30
Ex-Dividend Date 05/08/2026
Earnings Date 07/17/2026
Market Cap Chart
Data Updated: 07/20/2026

C-Rad AB (publ)'s yearly market capitalization.

C-Rad AB (publ) has seen its market value grow from £27.73 M to £97.65 M since 2014, representing a total increase of 252.13% and an annual compound growth rate (CAGR) of 11.51%.
Date Market Cap(£) Market Cap(USD) Change (%) Global Rank
07/20/2026 £97.65 M $131.38 M 0.59% 23776
12/30/2025 £86.64 M $114.44 M 18.87% 22451
12/30/2024 £72.88 M $91.18 M -34.12% 23849
12/29/2023 £110.63 M $140.83 M 8.01% 20945
12/30/2022 £102.43 M $123.87 M -33.48% 20908
12/30/2021 £153.99 M $208.16 M 5.75% 18606
12/30/2020 £145.62 M $0 29.16% 16800
12/30/2019 £112.74 M $149.5 M 61.69% 16115
12/28/2018 £69.73 M $88.91 M -11.37% 17872
12/29/2017 £78.67 M $106.22 M 147.77% 17667

Company Profile

About C-Rad AB (publ)

C-Rad AB (publ) is a global leader in developing, manufacturing, and selling advanced radiotherapy solutions for cancer treatment. The company operates across Europe, the Middle East, Africa, the Americas, and the Asia Pacific.

Core Products & Solutions

  • Sentinel 4DCT: A laser-based optical surface scanning system for precise radiotherapy.
  • Catalyst+ HD: A patient positioning and motion management solution for conventional and stereotactic treatments.
  • Catalyst+ PT: A surface image-guided radiation therapy system supporting proton therapy.
  • Catalyst+ HD Ring Gantry: Enhances patient positioning and real-time motion monitoring.
  • Catalyst Series: Includes 4D surface-guided radiation therapy (SGRT) solutions for various treatment needs.
  • cAutoVerify & cAccessory: Automation solutions for patient identity validation and accessory tracking.

Additional Offerings

  • SmartPhantom RT & StaticPhantom: Devices for laser alignment and precision verification.
  • High Impact Technology (HIT) Systems: Motorized laser positioning solutions for patient alignment.
  • Support & Training: Comprehensive service contracts and training programs.

Founded in 2004, C-Rad AB (publ) is headquartered in Uppsala, Sweden, and continues to innovate in the field of radiotherapy technology.

Frequently Asked Questions

  • What is C-Rad AB (publ)'s (LON-0R44) current market cap?
    As of 07/20/2026, C-Rad AB (publ) (including the parent company, if applicable) has an estimated market capitalization of $131.38 M USD. This figure represents the total market value of its outstanding shares, including different share classes. Please note that market capitalization fluctuates based on market conditions, and the actual valuation may differ from the latest estimate.
  • C-Rad AB (publ) global market capitalization ranking is approximately 23776 as of 07/20/2026. This ranking is relative to all publicly traded companies worldwide and can fluctuate based on market dynamics and the performance of other companies. You can refer to our Global companies market cap ranking for the most up-to-date ranking.

MarketCapWatch.com ranks all listed companies worldwide, providing unique insights into market capitalization across industries. As one of the most comprehensive ranking platforms, it covers companies of all sizes and sectors.

Research Tools

Copyright © 2026. All rights reserved

Important Disclaimer: All content provided on this website, including hyperlinked pages, related applications, forums, blogs, social media accounts, and other platforms ("the Site"), is for general informational purposes only and sourced from third-party providers. We make no guarantees regarding the accuracy, completeness, or timeliness of the content.

None of the information presented constitutes financial, legal, or professional advice. Users should conduct their own research, evaluation, and verification before making any decisions. Investing and trading carry significant risks that may lead to substantial losses. Therefore, we strongly recommend consulting a qualified financial advisor before taking any action.